自血光化学疗法对中晚期肿瘤放疗增敏的研究--104例的研究

目的将光量子疗法（Ｕｌｔｒａｖｉｏｌｅｔｂｌｏｏｄｉｒｒａｄｉｔｉｏｎ，ＵＢＩ）与光动力疗法（Ｐｈｏｔｏｄｙｎａｍｉｃｔｈｅｒａｐｙ，ＰＤＴ）的理论相结合，利用ＵＢＩ的氧效应ＰＤＴ的光敏作用，探讨其对肿瘤放疗的增敏作用。方法在体外将患者自体抗凝血（２００～３００ＭＬ）加入血卟啉衍生物（Ｈｅｍｏｔｏｐｏｒｐｈｙｒｉｎｄｅｒｉｖａｔｉｖｅ，ＨＰＤ），经紫外线照射后，回输给病人。回输给２４小时后，行６０钴或６ＭＶＸ线常规分割放疗，治疗中晚期恶性肿瘤１０４例。结果增敏组ＣＲ４６．２％（４８／１０４），ＰＲ４１．３％（４３／１０４），ＣＲ＋ＰＲ８７．５％（９１／１０４），１，２，３年生存率分别为６２．２％，１９．２％，１４．８％。肺癌增敏组与对照组的ＣＲ＋ＰＲ分别为８１．８％（５４／６６）及４４．７％（３０／６７）。子宫颈癌增敏组ＣＲ１００％（１３／１３），对照组ＣＲ６０％（６／１３）。对照组ＣＲ６０％（６／１３）。结论自血光化学疗法可提高中晚期肿瘤对放疗的敏感性，对肺癌、子宫颈癌的放疗增敏作用尤为显著。

Radiosensitization Effect of Photochemotherapy for Radiotherapy: a study of 104 patients

Objective:To investigate the radiosensitization effect of photochemotherapy for advanced neoplasma. Methods: 104 cases were treated by photochemotherapy plus radiotherapy. In vitro, blood from patient was mixed with hematoporphyrin (HPD) and oxyzen, irridiated with ultraviolet A. Then the blood was transfused back to the patient 24 hours later, the patient was radiated with 60 CO or xray of 6 MV Results:Among 104 patients with photochemotherapy plus radiotherapy, CR was 46.2% (48/104),PR 41.3%(43/104), CR PR 87.5%(91/104). In lung neoplasma, CR PR was 81.8% in photochemotherapy group and 44.7% in control group. In uterine cervix neoplasma, CR was 100%(13/13) in photochemotherapy group, 60%(6/13) in control group. Conclusion:Photochemotherapy can increas the sensitivity of advanced neoplasma to radiotherapy.